[Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.10.1097/01.MIB.0000195385.19268.68]Search in Google Scholar
[Repiso A, Alcantara M, Munoz-Rosas C, Rodriguez-Merlo R, Perez-Grueso MJ, Carrobles JM, Carrobles JM, Martinez-Potenciano JL. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-7.10.4321/S1130-01082006000700004]Search in Google Scholar
[Sands BE, Grabert S. Epidemiology of inflammatory bowel disease and overview of pathogenesis. Med Health R I 2009;92:73-7.]Search in Google Scholar
[Hibi T. Molecular biological studies of the pathogenesis in inflammatory bowel disease. Intern Med 2003;42:285-7.10.2169/internalmedicine.42.285]Search in Google Scholar
[Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH.; Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept - what's in a name? Inflamm Bowel Dis 2008;14:850-7.]Search in Google Scholar
[Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e1-10.10.1016/j.tripleo.2009.07.035]Search in Google Scholar
[Baticic L, Detel D, Kucic N, Buljevic S, Pugel EP, Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011;112:3322-33.10.1002/jcb.23261]Search in Google Scholar
[Hildebrandt M, Rose M, Rüter J, Salama A, Mönnikes H, Klapp BF. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001;36:1067-72.10.1080/003655201750422675]Search in Google Scholar
[Varljen J, Mijandrušić Sinčić B, Batičić L, Varljen N, Detel D, Lekić A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat Chem Acta 2005;78:427-32.]Search in Google Scholar
[Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.10.1053/j.gastro.2004.01.063]Search in Google Scholar
[Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.10.1016/S0140-6736(07)60750-8]Search in Google Scholar
[Niv Y, Abuksis G, Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000;95:693-8.10.1111/j.1572-0241.2000.01849.x10710059]Search in Google Scholar
[Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, Steinwurz F, Vatn MH, Yamamoto-Furusho JK. IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 - Inflammatory bowel disease task force meeting. Inflamm Bowel Dis 2011;17:639-44.10.1002/ibd.2140920725944]Search in Google Scholar
[Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16-25.10.1007/s00535-006-1995-7278067417322989]Search in Google Scholar
[Sincić BM, Vucelić B, Persić M, Brncić N, Erzen DJ, Radaković B, Mićović V, Stimac D. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006;41:437-44.10.1080/0036552050032009416635912]Search in Google Scholar
[Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010;6:339-46.]Search in Google Scholar
[Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blakenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.10.1136/gut.39.5.69013833939014768]Search in Google Scholar
[Van Limbergen J, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol 2007;102:2820-31.10.1111/j.1572-0241.2007.01527.x17894847]Search in Google Scholar
[Satsangi J, Morecroft J, Shah NB, Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003;17:3-18.10.1053/bega.2002.034912617879]Search in Google Scholar
[Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep 2002;4:481-9.10.1007/s11894-002-0024-012441038]Search in Google Scholar
[Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.10.1128/CMR.15.1.79-94.200211806111781268]Search in Google Scholar
[Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J. Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol 2006;12:1991-9.10.3748/wjg.v12.i13.1991408767416610046]Search in Google Scholar
[Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.10.1038/nri113212876555]Search in Google Scholar
[Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Puig LP, Rousseau GC, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.10.1038/3507910711385576]Search in Google Scholar
[Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar J-P, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.10.1038/35079114]Search in Google Scholar
[Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, Satsangi J. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55.10.1002/ibd.20096]Search in Google Scholar
[Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.10.1056/NEJMra020831]Search in Google Scholar
[Colletti T. IBD - recognition, diagnosis, therapeutics. JAAPA 2004;17:16-18, 21-14.]Search in Google Scholar
[Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:41-62.10.1016/S0889-8553(01)00004-8]Search in Google Scholar
[MacDonald TT. Gastrointestinal inflammation. Inflammatory bowel disease in knockout mice. Curr Biol 1994;4:261-3.10.1016/S0960-9822(00)00060-9]Search in Google Scholar
[Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Schölmerich J, Balfour Sartor R. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.10.1128/IAI.69.4.2277-2285.20019815611254584]Search in Google Scholar
[Cucchiara S, Iebba V, Conte MP, Schippa S. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009;27:252-8.10.1159/00022855819786749]Search in Google Scholar
[Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol 2008;103:1775-82.10.1111/j.1572-0241.2008.01905.x18557710]Search in Google Scholar
[Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol 2009;60(Suppl 6):61-71.]Search in Google Scholar
[Sanz Y, De Palma G. Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol 2009;28:397-413.10.3109/0883018090321561319954356]Search in Google Scholar
[Shah SA, Feller ER. Inflammatory bowel disease. Med Health R I 2009;92:72.]Search in Google Scholar
[Sonnenberg A. Occupational mortality of inflammatory bowel disease. Digestion 1990;46:10-8.10.1159/0002002732210092]Search in Google Scholar
[Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, Villeneuve PJ. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105:2412-9.10.1038/ajg.2010.252]Search in Google Scholar
[Henderson P, van Limbergen JE, Schwarze J, Wilson DC. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:382-95.10.1002/ibd.21379]Search in Google Scholar
[Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease - epidemiology and treatment. Aliment Pharmacol Ther 2009;30:99-112.10.1111/j.1365-2036.2009.04035.x]Search in Google Scholar
[Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47-52.10.1097/00001648-199201000-00009]Search in Google Scholar
[Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280-9.10.1111/j.1753-4887.2010.00287.x]Search in Google Scholar
[Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis 2008;14(Suppl 2):S14-15.10.1002/ibd.20555]Search in Google Scholar
[van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009;15:1199-207.10.1002/ibd.20884]Search in Google Scholar
[Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009;33(Suppl 3):S145-57.10.1016/S0399-8320(09)73150-1]Search in Google Scholar
[Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481-96.10.1016/j.bpg.2003.12.00315157822]Search in Google Scholar
[Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 2009;27:215-25.10.1159/00022855319786744]Search in Google Scholar
[Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006;66:424-9.10.1016/j.ijrobp.2006.05.027]Search in Google Scholar
[Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 2009;158:272-80.10.1111/j.1365-2249.2009.04033.x]Search in Google Scholar
[Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G175-84.10.1152/ajpgi.90454.2008]Search in Google Scholar
[Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004;235:165-213.10.1016/S0074-7696(04)35004-7]Search in Google Scholar
[Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009;16:2943-51.10.2174/092986709788803114]Search in Google Scholar
[Van der Veken P, Haemers A, Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Topics Med Chem 2007;7:621-35.10.2174/156802607780091046]Search in Google Scholar
[Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001;1550:107-16.10.1016/S0167-4838(01)00278-3]Search in Google Scholar
[Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723-47.10.1007/s00262-009-0728-119557413]Search in Google Scholar
[Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999;29:1768-78.10.1002/hep.51029063110347120]Search in Google Scholar
[Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41.10.1158/1078-0432.CCR-06-174617363526]Search in Google Scholar
[Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35.]Search in Google Scholar
[Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000;20:1089-94.10.1128/MCB.20.3.1089-1094.20008522610629066]Search in Google Scholar
[Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000;267:6140-50.10.1046/j.1432-1327.2000.01617.x11012666]Search in Google Scholar
[Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpé S, De Meester I. Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 2009;57:531-41.10.1369/jhc.2009.952739269040619188489]Search in Google Scholar
[Chen T, Smyth D, Abbott CA. Cd26. J Biolo Regul Homeost Agents 2004;18:47-54.]Search in Google Scholar
[Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.10.1042/CS2004030215584901]Search in Google Scholar
[Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73.10.1078/0171-9335-0030212647932]Search in Google Scholar
[Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist KG. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009;183:3616-24.10.4049/jimmunol.080433619687096]Search in Google Scholar
[Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpé S. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009;47:248-52.]Search in Google Scholar
[Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966;7:197-201.10.1007/BF005778385959122]Search in Google Scholar
[Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 1993;177:1135-43.10.1084/jem.177.4.113521909628096237]Search in Google Scholar
[Lojda Z. Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry 1977;54:299-309.10.1007/BF00508273599045]Search in Google Scholar
[Kullertz G, Fischer G, Barth A. [Catalytic mechanism of dipeptidyl-peptidase IV, in German]. Acta Biol Med Ger 1978;37:559-67.]Search in Google Scholar
[Hanski C, Huhle T, Reutter W. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 1985;366:1169-76.10.1515/bchm3.1985.366.2.11692868739]Search in Google Scholar
[Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.10.1016/S0167-0115(99)00089-0]Search in Google Scholar
[Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem 1992;267:4824-33.10.1016/S0021-9258(18)42906-7]Search in Google Scholar
[Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci U S A 2001;98:12138-43.10.1073/pnas.211439098]Search in Google Scholar
[Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003;7:496-504.10.1016/S1367-5931(03)00084-X]Search in Google Scholar
[Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.10.1182/blood.V82.4.1052.bloodjournal8241052]Search in Google Scholar
[Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64.10.1046/j.1365-3083.2001.00984.x]Search in Google Scholar
[Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180-4.10.1016/0167-5699(94)90316-6]Search in Google Scholar
[Muñoz E, Blazquez MV, Madueño JA, Rubio G, Peña J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 1992;77:43-50.]Search in Google Scholar
[Bednarczyk JL, Carroll SM, Marin C, McIntyre BW. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991;46:206-18.10.1002/jcb.240460304]Search in Google Scholar
[Bühling F, Junker U, Reinhold D, Neubert K, Jäger L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47-51.10.1016/0165-2478(94)00230-O]Search in Google Scholar
[Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999;4:3-15.10.3892/ijmm.4.1.310373631]Search in Google Scholar
[Fleischer B, Sturm E, De Vries JE, Spits H. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J Immunol 1988;141:1103-7.10.4049/jimmunol.141.4.1103]Search in Google Scholar
[Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.10.1182/blood.V79.12.3239.bloodjournal79123239]Search in Google Scholar
[Bühling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 1994;13:270-9.]Search in Google Scholar
[Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994;40:331-8.10.1007/BF01246674]Search in Google Scholar
[Böhm SK, Gum JR, Jr., Erickson RH, Hicks JW, Kim YS. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem J 1995;311(Pt 3):835-43.10.1042/bj3110835]Search in Google Scholar
[Misumi Y, Hayashi Y, Arakawa F, Ikehara Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta 1992;1131:333-6.10.1016/0167-4781(92)90036-Y]Search in Google Scholar
[Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth H-U, Brandstetter H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A 2003;100:5063-8.10.1073/pnas.0230620100]Search in Google Scholar
[Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.10.1038/nsb882]Search in Google Scholar
[Bjelke JR, Christensen J, Branner S, Wagtmann N, Olsen C, Kanstrup AB, Rasmussen HB. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. J Biol Chem 2004;279:34691-7.10.1074/jbc.M405400200]Search in Google Scholar
[Van Damme J, Struyf S, Wuyts A, Van Coillie E, Menten P, Schols D, Sozzani S, De Meester I, Proost P. The role of CD26/DPP IV in chemokine processing. Chem Immunol 1999;72:42-56.10.1159/000058725]Search in Google Scholar
[Hoffmann T, Faust J, Neubert K, Ansorge S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 1993;336:61-4.10.1016/0014-5793(93)81609-4]Search in Google Scholar
[Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpé S. Proline motifs in peptides and their biological processing. Faseb J 1995;9:736-44.10.1096/fasebj.9.9.7601338]Search in Google Scholar
[Wang XM, Yu DM, McCaughan GW, Gorrell MD. Extra-enzymatic roles of DPIV and FAP in cell adhesion and migration on collagen and fibronectin. Adv Exp Med Biol 2006;575:213-22.10.1007/0-387-32824-6_2316700525]Search in Google Scholar
[Martinez-Navio JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M, Oliva H, Rovira C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009;128:393-404.10.1111/j.1365-2567.2009.03121.x277068720067539]Search in Google Scholar
[Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.10.1016/j.stem.2010.04.00120569697]Search in Google Scholar
[Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Täger M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47:253-61.10.1515/CCLM.2009.06319327105]Search in Google Scholar
[Reinhold D, Goihl A, Wrenger S, Reinhold A, Kühlmann UC, Faust J, Neubert K, Thielitz A, Brocke S, Täger M, Ansorge S, Bank U. Review: Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009;47:268-74.10.1515/CCLM.2009.06219676138]Search in Google Scholar
[De Meester I, Scharpé S, Lambeir AM. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin Chem Lab Med 2009;47:245-7.10.1515/CCLM.2009.08519327103]Search in Google Scholar
[Schön E, Eichmann E, Grunow R, Jahn S, Kiessig ST, Volk HD, Ansorge S. Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta 1986;45:1523-8.]Search in Google Scholar
[Reinhold D, Kähne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem 2002;383:1133-8.10.1515/BC.2002.12312437097]Search in Google Scholar
[Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;161:27-42.10.1111/j.1600-065X.1998.tb01569.x]Search in Google Scholar
[Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005;102:9583-8.10.1073/pnas.0501050102117224015983379]Search in Google Scholar
[Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 2007;7:253-73.10.2174/13895570778005985317346218]Search in Google Scholar
[Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:11-8.10.2174/156800804334003515032621]Search in Google Scholar
[Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7.10.1016/j.tips.2009.08.00319837468]Search in Google Scholar
[Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.10.1080/71360935412892317]Search in Google Scholar
[Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl 5):S4-11.10.3949/ccjm.76.s5.0219952303]Search in Google Scholar
[Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist. J Am Pharm Assoc 2009;49(Suppl 1):S2.10.1331/JAPhA.2009.0953719801362]Search in Google Scholar
[Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med 2009;121:70-100.10.3810/pgm.2009.11.207919940419]Search in Google Scholar
[Ahrén B. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 2007;7:340-7.10.1007/s11892-007-0056-918173966]Search in Google Scholar
[Lupi R, Del Guerra S, D'Aleo V, Boggi U, Filipponi F, Marchetti P. The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets. Regul Pept 2010;165:129-32.10.1016/j.regpep.2010.04.00920472004]Search in Google Scholar
[Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci 2000;99:93-104.10.1042/CS19990368]Search in Google Scholar
[Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci 2008;13:3699-713.10.2741/296018508466]Search in Google Scholar
[Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-8.10.1136/gut.43.1.71]Search in Google Scholar
[Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000;141:4013-20.10.1210/endo.141.11.7752]Search in Google Scholar
[Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001;142:521-7.10.1210/endo.142.2.7983]Search in Google Scholar
[Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharmaceut Design 2006;12:1731-50.10.2174/138161206776873671]Search in Google Scholar
[Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-91.10.1152/ajpgi.1999.276.1.G79]Search in Google Scholar
[Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84.10.1152/ajpendo.1997.273.1.E77]Search in Google Scholar
[Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol 1997;15:673-7.10.1038/nbt0797-673]Search in Google Scholar
[Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27.10.1002/eji.200323469]Search in Google Scholar
[Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.10.1016/0092-8674(93)80067-O]Search in Google Scholar
[Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.10.1016/0092-8674(93)80068-P]Search in Google Scholar
[Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.10.1016/0016-5085(95)90599-5]Search in Google Scholar
[Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Prot Immunol 2002;Chapter 15: Unit 15.19.]Search in Google Scholar
[Uhlig HH, Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. Eur J Immunol 2009;39:2021-6.10.1002/eji.200939602]Search in Google Scholar
[Grisham MB, Volkmer C, Tso P, Yamada T. Metabolism of trinitrobenzene sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 1991;101:540-7.10.1016/0016-5085(91)90036-K]Search in Google Scholar
[Ardite E, Sans M, Panés J, Romero FJ, Piqué JM, Fernández-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 2000;80:735-44.10.1038/labinvest.3780077]Search in Google Scholar
[Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83.10.1016/j.addr.2007.07.003]Search in Google Scholar
[Hans W, Schölmerich J, Gross V, Falk W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 2000;12:267-73.10.1097/00042737-200012030-00002]Search in Google Scholar
[Axelsson LG, Landström E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998;12:925-34.10.1046/j.1365-2036.1998.00357.x]Search in Google Scholar
[Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993;38:1722-34.10.1007/BF01303184]Search in Google Scholar
[Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13:251-60.10.1046/j.1365-2036.1999.00457.x]Search in Google Scholar
[Ohkusa T. [Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora, in Japanese]. Nippon Shokakibyo Gakkai Zasshi 1985;82:1327-36.]Search in Google Scholar
[Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.10.1016/0016-5085(90)90290-H]Search in Google Scholar
[Yamada M, Ohkusa T, Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992;33:1521-27.10.1136/gut.33.11.1521]Search in Google Scholar
[Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000;62:240-8.10.1159/000007822]Search in Google Scholar
[Bailey RW, Bourne EJ. Intracellular glycosidases of dextran-producing bacteria. Nature 1961;191:277-8.10.1038/191277a0]Search in Google Scholar
[Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000;49:9-15.10.1538/expanim.49.9]Search in Google Scholar
[Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scand J Gastroenterol 2000;35:1053-9.10.1080/003655200451171]Search in Google Scholar
[Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007;140:12-9.10.1016/j.jss.2006.07.050]Search in Google Scholar
[Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 1996;39:234-41.10.1136/gut.39.2.234]Search in Google Scholar
[Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A 2002;99:14338-43.10.1073/pnas.212290499]Search in Google Scholar
[Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.]Search in Google Scholar
[Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpe S, De Meester I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001;507:327-30.10.1016/S0014-5793(01)02982-9]Search in Google Scholar
[Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133-44.10.1016/0167-0115(93)90435-B]Search in Google Scholar
[Bouras M, Huneau JF, Luengo C, Erlanson-Albertsson C, Tomé D. Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases. Peptides 1995;16:399-405.10.1016/0196-9781(94)00213-P]Search in Google Scholar
[Nausch I, Mentlein R, Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler 1990;371:1113-8.10.1515/bchm3.1990.371.2.1113]Search in Google Scholar
[Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpé S, De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-13.10.1046/j.1432-1327.2000.01634.x]Search in Google Scholar
[Kato T, Nagatsu T, Fukasawa K, Harada M, Nagatsu I, Sakakibara S. Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase. Biochim Biophys Acta 1978;525:417-22.10.1016/0005-2744(78)90237-1]Search in Google Scholar
[Heymann E, Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 1978;91:360-4.10.1016/0014-5793(78)81210-1]Search in Google Scholar
[Shane R, Wilk S, Bodnar RJ. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 1999;815:278-86.10.1016/S0006-8993(98)01121-4]Search in Google Scholar
[Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72.10.1084/jem.186.11.186521991489382885]Search in Google Scholar
[Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S, Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222-7.10.1074/jbc.273.13.72229516414]Search in Google Scholar
[Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 1998;95:6331-6.10.1073/pnas.95.11.6331276829600965]Search in Google Scholar
[Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpé S, Van Damme J, De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-93.10.1074/jbc.274.7.39889933589]Search in Google Scholar
[Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP, Detheux M, Parmentier M, De Meester I, Scharpé S, Van Damme J. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162:4903-9.10.4049/jimmunol.162.8.4903]Search in Google Scholar
[Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.10.1111/j.1432-1033.1993.tb17986.x]Search in Google Scholar
[Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992;1122:147-53.10.1016/0167-4838(92)90317-7]Search in Google Scholar